D.A. Davidson & Co’s Checkpoint Therapeutics CKPT Stock Holding History

D.A. Davidson & Co’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,500	Closed	-$23.5K	–	1434
2024 Q3	$23.5K	Sell	10,500 -500	-5%	-$1.15K	﹤0.01%	1367
2024 Q2	$23.6K	Buy	+11,000	New	+$19.6K	﹤0.01%	1353
2023 Q4	–	Sell	-10,000	Closed	-$17K	–	1375
2023 Q3	$17K	Hold	10,000	–	–	﹤0.01%	1316
2023 Q2	$24.7K	Buy	+10,000	New	+$27.3K	﹤0.01%	1322

Other funds holding CKPT

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.A. Davidson & Co's CKPT Position: Q4 2024 in Review

D.A. Davidson & Co sold out of Checkpoint Therapeutics (CKPT) in Q4 2024, closing a stake of 10,500 shares — an estimated $23.5K sold.

D.A. Davidson & Co first reported a position in CKPT in Q2 2023 and held it in 4 quarters. The position peaked at $24.7K in Q2 2023. 68 funds tracked by Wall St. Rank hold CKPT as of Q4 2024.

D.A. Davidson & Co reported no remaining Checkpoint Therapeutics position as of Q4 2024 after selling out during the quarter.
D.A. Davidson & Co sold 10,500 Checkpoint Therapeutics shares in Q4 2024, an estimated $23.5K.
D.A. Davidson & Co first reported a position in Checkpoint Therapeutics in Q2 2023 and held it in 4 quarters.
D.A. Davidson & Co's Checkpoint Therapeutics position peaked at $24.7K in Q2 2023.
68 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2024.

Based on D.A. Davidson & Co's 13F filing for Q4 2024, filed 31 Jan 2025.